Chinese General Practice ›› 2022, Vol. 25 ›› Issue (14): 1730-1735.DOI: 10.12114/j.issn.1007-9572.2022.0022
• Article • Previous Articles Next Articles
Received:
2021-12-01
Revised:
2022-02-22
Published:
2022-03-31
Online:
2022-04-07
Contact:
Aihong MENG
About author:
通讯作者:
孟爱宏
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0022
组别 | 例数 | 年龄( | 性别〔n(%)〕 | BMI( | 吸烟〔n(%)〕 | 吸烟量〔M(Q1,Q3),包·年〕 | FEV1%pred( | PaO2( | |
---|---|---|---|---|---|---|---|---|---|
男 | 女 | ||||||||
EOS组 | 120 | 69.5±8.6 | 111(92.5) | 9(7.5) | 22.79±4.04 | 112(36.6) | 30(20,50) | 46.61±18.10 | 71±15 |
非EOS组 | 206 | 68.7±8.8 | 194(94.2) | 12(5.8) | 22.92±3.55 | 194(63.4) | 30(20,50) | 44.77±18.30 | 69±15 |
检验统计量值 | 0.732a | 0.353b | 0.260a | 0.093b | 10 525.000 | 0.882a | 1.255a | ||
P值 | 0.465 | 0.552 | 0.786 | 0.760 | 0.538 | 0.391 | 0.210 | ||
组别 | PaCO2( | hs-CRP〔M(Q1,Q3),mg/L〕 | NE绝对值〔M(Q1,Q3),×109/L〕 | NLR〔M(Q1,Q3)〕 | FIB( | ALB( | FAR〔M(Q1,Q3)〕 | ||
EOS组 | 47±9 | 5.3(0,19.6) | 4.25(2.04,6.46) | 2.91(1.02,4.80) | 3.52±0.83 | 37.50±4.40 | 0.08(0.07,0.09) | ||
非EOS组 | 49±10 | 12.5(0,4.0) | 5.57(0.66,10.48) | 4.58(1.35,7.81) | 3.61±0.98 | 36.40±4.60 | 0.09(0.06,0.12) | ||
检验统计量值 | 1.426a | 10 388.000 | 9 928.500 | 8 265.000 | 2.112a | 2.114a | 9 967.000 | ||
P值 | 0.173 | 0.005 | 0.003 | <0.001 | 0.404 | 0.035 | 0.003 |
Table 1 Comparison of clinical data between EOS group and non-EOS group
组别 | 例数 | 年龄( | 性别〔n(%)〕 | BMI( | 吸烟〔n(%)〕 | 吸烟量〔M(Q1,Q3),包·年〕 | FEV1%pred( | PaO2( | |
---|---|---|---|---|---|---|---|---|---|
男 | 女 | ||||||||
EOS组 | 120 | 69.5±8.6 | 111(92.5) | 9(7.5) | 22.79±4.04 | 112(36.6) | 30(20,50) | 46.61±18.10 | 71±15 |
非EOS组 | 206 | 68.7±8.8 | 194(94.2) | 12(5.8) | 22.92±3.55 | 194(63.4) | 30(20,50) | 44.77±18.30 | 69±15 |
检验统计量值 | 0.732a | 0.353b | 0.260a | 0.093b | 10 525.000 | 0.882a | 1.255a | ||
P值 | 0.465 | 0.552 | 0.786 | 0.760 | 0.538 | 0.391 | 0.210 | ||
组别 | PaCO2( | hs-CRP〔M(Q1,Q3),mg/L〕 | NE绝对值〔M(Q1,Q3),×109/L〕 | NLR〔M(Q1,Q3)〕 | FIB( | ALB( | FAR〔M(Q1,Q3)〕 | ||
EOS组 | 47±9 | 5.3(0,19.6) | 4.25(2.04,6.46) | 2.91(1.02,4.80) | 3.52±0.83 | 37.50±4.40 | 0.08(0.07,0.09) | ||
非EOS组 | 49±10 | 12.5(0,4.0) | 5.57(0.66,10.48) | 4.58(1.35,7.81) | 3.61±0.98 | 36.40±4.60 | 0.09(0.06,0.12) | ||
检验统计量值 | 1.426a | 10 388.000 | 9 928.500 | 8 265.000 | 2.112a | 2.114a | 9 967.000 | ||
P值 | 0.173 | 0.005 | 0.003 | <0.001 | 0.404 | 0.035 | 0.003 |
组别 | 例数 | 肺部应用激素〔n(%)〕 | 全身应用激素〔n(%)〕 | 激素应用总量〔M(Q1,Q3),mg〕 | 激素疗程〔M(Q1,Q3),mg〕 | 住院时间( |
---|---|---|---|---|---|---|
EOS组 | 120 | 87(72.5) | 15(12.5) | 21(0,45) | 7(5,9) | 10.0±3.0 |
非EOS组 | 206 | 190(92.2) | 53(25.7) | 30(16,44) | 9(6,12) | 10.9±2.7 |
检验统计量值 | 23.12a | 8.04a | 5 547.00 | 51 235.00 | -2.85b | |
P值 | <0.001 | 0.005 | <0.001 | <0.001 | 0.001 |
Table 2 Comparison of length of hospital stay and hormone application between EOS group and non-EOS group
组别 | 例数 | 肺部应用激素〔n(%)〕 | 全身应用激素〔n(%)〕 | 激素应用总量〔M(Q1,Q3),mg〕 | 激素疗程〔M(Q1,Q3),mg〕 | 住院时间( |
---|---|---|---|---|---|---|
EOS组 | 120 | 87(72.5) | 15(12.5) | 21(0,45) | 7(5,9) | 10.0±3.0 |
非EOS组 | 206 | 190(92.2) | 53(25.7) | 30(16,44) | 9(6,12) | 10.9±2.7 |
检验统计量值 | 23.12a | 8.04a | 5 547.00 | 51 235.00 | -2.85b | |
P值 | <0.001 | 0.005 | <0.001 | <0.001 | 0.001 |
组别 | 例数 | 年龄( | 性别〔n(%)〕 | BMI( | 吸烟〔n(%)〕 | 吸烟量〔M(Q1,Q3),包·年〕 | FEV1%pred〔M(Q1,Q3),%〕 | 肺功能重度〔M(Q1,Q3),%〕 | PaO2〔M(Q1,Q3),mm Hg〕 | |
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||||
EOS组 | 120 | 69.5±8.6 | 111(92.5) | 9(7.5) | 22.79±4.04 | 111(55.8) | 30(20,50) | 43.96(15.35,72.57) | 40.95(31.70,50.20) | 69(46,92) |
ACO组 | 157 | 64.7±9.8 | 99(63.1) | 58(36.9) | 24.50±3.46 | 88(44.2) | 30(20,50) | 53.27(30.97,75.57) | 48.20(38.00,58.40) | 75(60,90) |
检验统计量值 | 4.262a | 32.15b | -3.761a | 46.635b | 10 412.000 | 7 479.000 | 802.000 | 2 775.000 | ||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.695 | <0.001 | <0.001 | 0.351 | ||
组别 | PaCO2〔M(Q1,Q3),mm Hg〕 | hs-CRP〔M(Q1,Q3),mg/l〕 | NE绝对值〔M(Q1,Q3),×109/L〕 | NLR〔M(Q1,Q3)〕 | FIB〔M(Q1,Q3),g/L〕 | ALB( | FAR〔M(Q1,Q3)〕 | EOS%≥2%〔n(%)〕 | ||
EOS组 | 46(31,61) | 5.75(0,21.95) | 4.25(2.04,6.46) | 2.91(1.02,4.80) | 3.29(2.46,4.11) | 37.50±4.40 | 0.08(0.07,0.09) | 120(100.00) | ||
ACO组 | 41(26,56) | 5.90(0,22.10) | 4.98(0.91,9.05) | 3.78(0.19,7.37) | 3.41(2.68,4.41) | 38.08±4.34 | 0.09(0.07,0.11) | 66(42.00) | ||
检验统计量值 | 5 784.000 | 167.000 | 6 937.500 | 6 721.000 | 157.000 | 1.448a | 4 471.000 | 103.583b | ||
P值 | 0.078 | 0.663 | 0.031 | 0.026 | 0.664 | 0.278 | 0.266 | <0.001 |
Table 3 Comparison of clinical data of EOS group and ACO group
组别 | 例数 | 年龄( | 性别〔n(%)〕 | BMI( | 吸烟〔n(%)〕 | 吸烟量〔M(Q1,Q3),包·年〕 | FEV1%pred〔M(Q1,Q3),%〕 | 肺功能重度〔M(Q1,Q3),%〕 | PaO2〔M(Q1,Q3),mm Hg〕 | |
---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | |||||||||
EOS组 | 120 | 69.5±8.6 | 111(92.5) | 9(7.5) | 22.79±4.04 | 111(55.8) | 30(20,50) | 43.96(15.35,72.57) | 40.95(31.70,50.20) | 69(46,92) |
ACO组 | 157 | 64.7±9.8 | 99(63.1) | 58(36.9) | 24.50±3.46 | 88(44.2) | 30(20,50) | 53.27(30.97,75.57) | 48.20(38.00,58.40) | 75(60,90) |
检验统计量值 | 4.262a | 32.15b | -3.761a | 46.635b | 10 412.000 | 7 479.000 | 802.000 | 2 775.000 | ||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | 0.695 | <0.001 | <0.001 | 0.351 | ||
组别 | PaCO2〔M(Q1,Q3),mm Hg〕 | hs-CRP〔M(Q1,Q3),mg/l〕 | NE绝对值〔M(Q1,Q3),×109/L〕 | NLR〔M(Q1,Q3)〕 | FIB〔M(Q1,Q3),g/L〕 | ALB( | FAR〔M(Q1,Q3)〕 | EOS%≥2%〔n(%)〕 | ||
EOS组 | 46(31,61) | 5.75(0,21.95) | 4.25(2.04,6.46) | 2.91(1.02,4.80) | 3.29(2.46,4.11) | 37.50±4.40 | 0.08(0.07,0.09) | 120(100.00) | ||
ACO组 | 41(26,56) | 5.90(0,22.10) | 4.98(0.91,9.05) | 3.78(0.19,7.37) | 3.41(2.68,4.41) | 38.08±4.34 | 0.09(0.07,0.11) | 66(42.00) | ||
检验统计量值 | 5 784.000 | 167.000 | 6 937.500 | 6 721.000 | 157.000 | 1.448a | 4 471.000 | 103.583b | ||
P值 | 0.078 | 0.663 | 0.031 | 0.026 | 0.664 | 0.278 | 0.266 | <0.001 |
组别 | 例数 | 肺部应用激素〔n(%)〕 | 全身应用激素〔n(%)〕 | 激素应用总量〔M(Q1,Q3),mg〕 | 激素疗程〔M(Q1,Q3),d〕 | 住院时间〔M(Q1,Q3),d〕 |
---|---|---|---|---|---|---|
EOS组 | 120 | 87(72.5) | 15(12.5) | 21(0,45) | 7(5,9) | 10(6,14) |
ACO组 | 157 | 146(93.0) | 77(49.0) | 27(0,78) | 8(5,11) | 9(8,10) |
χ2(Z)值 | 49.014a | 40.950a | 4 880.000 | 6 377.000 | 5 416.000 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 4 Comparison of hospital stay and hormone application between EOS group and ACO group
组别 | 例数 | 肺部应用激素〔n(%)〕 | 全身应用激素〔n(%)〕 | 激素应用总量〔M(Q1,Q3),mg〕 | 激素疗程〔M(Q1,Q3),d〕 | 住院时间〔M(Q1,Q3),d〕 |
---|---|---|---|---|---|---|
EOS组 | 120 | 87(72.5) | 15(12.5) | 21(0,45) | 7(5,9) | 10(6,14) |
ACO组 | 157 | 146(93.0) | 77(49.0) | 27(0,78) | 8(5,11) | 9(8,10) |
χ2(Z)值 | 49.014a | 40.950a | 4 880.000 | 6 377.000 | 5 416.000 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
[1] |
|
[2] |
|
[3] |
|
[4] |
薛瑾,崔亚楠,陈平,等. 血嗜酸粒细胞对慢性阻塞性肺疾病急性加重期激素治疗反应性和再入院的预测价值[J]. 中华结核和呼吸杂志,2019,42(6):426-431. DOI:10.3760/cma.j.issn.1001-0939.2019.06.005.
|
[5] |
|
[6] |
|
[7] |
GOLD Executive Committee. Global strategy for the diagnosis,management and prevention of chronic obstructive pulmonary disease 2020 report [EB/OL]. [2021-01-24].
|
[8] |
|
[9] |
|
[10] | |
[11] |
|
[12] |
|
[13] |
|
[14] |
肖华叶,梁斌苗,欧雪梅. 中性粒细胞与淋巴细胞比值在慢性阻塞性肺疾病急性加重期中的价值[J]. 中国呼吸与危重监护杂志,2021,20(2):85-90. DOI:10.7507/1671-6205.201911050.
|
[15] |
|
[16] |
赵赟,王锐英,许建英,等.不同水平血嗜酸粒细胞的慢性阻塞性肺疾病急性加重期患者的临床特征[J]. 国际呼吸杂志,2020,40(17):1309-1313. DOI:10.3760/cma.j.cn131368-20191127-01668.
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[1] | ZHANG Yanjing, SONG Xiaokun. Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors [J]. Chinese General Practice, 2023, 26(23): 2930-2935. |
[2] | RAO Yufeng, MENG Liheng, ZHOU Jia, LIANG Xinghuan, HUANG Zhenxing, QIN Yingfen. Phenotypically Male Congenital Adrenal Hyperplasia Patient with Huge Space-occupying Adrenal Masses: a Case Report and Literature Review [J]. Chinese General Practice, 2023, 26(21): 2690-2694. |
[3] | Ke QIN, Tonglin LI, Shuai GONG, Meifang JIANG. Changes and Response Predictive Values of Serum miR-210 and miR-181a in Stable Chronic Obstructive Pulmonary Disease Patients Treated with Glucocorticoid Therapy [J]. Chinese General Practice, 2022, 25(24): 3013-3017. |
[4] | Ting PAN, Tieying SUN. Progress of Anticancer Drug-induced Organizing Pneumonia [J]. Chinese General Practice, 2022, 25(14): 1772-1778. |
[5] | Yide WANG, Zongxiang TIAN, Zheng LI, Fengsen LI. Pulmonary Function and Imaging Characteristics of Tuberculosis Associated Obstructive Pulmonary Disease Using Propensity Score-matched Analysis [J]. Chinese General Practice, 2022, 25(14): 1718-1723. |
[6] |
YU Xinxin, ZHENG Jinping, GAO Yi, XIE Yanqing, AN Jiaying, LIU Wenting, ZHONG Liping, WU Zhongping, ZHU Zheng.
Iurnal Variability of Airway Hyperresponsiveness in Asthma Patients [J]. Chinese General Practice, 2022, 25(11): 1351-1356. |
[7] |
ZHOU Lijuan, WEN Xianxiu, LYU Qin, JIANG Rong, WU Xingwei, ZHOU Huangyuan, XIANG Chao.
Using Machine Learning to Build an Early Warning Model for the Risk of Severe Airflow Limitation in Patients with Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2022, 25(02): 217-226. |
[8] | WANG Xiaosheng,KANG Xiaoling,ZHANG Ying,SUN Baohua. Role of Induced Sputum and Fractional Exhaled Nitric Oxide Test for Assessing Inflammation in Patients with Bronchiectasis [J]. Chinese General Practice, 2021, 24(5): 546-550. |
[9] | ZHANG Shengxin,YUAN Lin,ZHUO Zhiqiang,LI Mingzhen,TONG Xiubin. Clinical Value of Fractional Exhaled Nitric Oxide and Lung Function by Tidal Breathing in Children with Bronchiolitis [J]. Chinese General Practice, 2021, 24(5): 551-554. |
[10] | GAO Jie,GAO Yun,ZHANG Mingfeng,AN Zhenmei,WU Yuelei,ZHANG Qin. Factors Associated with Increased Risk of SARS-CoV-2 Infections in Diabetics [J]. Chinese General Practice, 2020, 23(35): 4436-4442. |
[11] | XIN Qingfeng,SUN Youli,KANG Meiqing,LI Chaoyan. Efficacy and Delay of Recurrence in Cough Variant Asthma Patients Treated with Salmeterol/Fluticasone [J]. Chinese General Practice, 2020, 23(26): 3280-3285. |
[12] | ZHAO Linlin,WANG Shoujun. The Clinical Characteristics of Type B Insulin Resistance [J]. Chinese General Practice, 2020, 23(11): 1431-1435. |
[13] | WANG Xiaojuan,FANG Xiangyang. Interpretation of the Global Strategy for the Diagnosis,Management,and Prevention of COPD 2019 by GOLD [J]. Chinese General Practice, 2019, 22(18): 2141-2149. |
[14] | LI Wenkun,LIU Kuiliang,WU Jing. Analysis of Clinical Features of 22 Cases of Cryptogenic Multifocal Ulcerous Stenosing Enteritis [J]. Chinese General Practice, 2018, 21(36): 4527-4530. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||